Avoro Capital Advisors LLC
An institutional investment manager in NEW YORK, NY. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1633313.
- Reported value$11.14bn
- Positions26
Holdings: 26 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| United Therapeutics CorpUTHR | Common | 91307C102 | 1,505 | 13.5% | 2,777,777 | Added+147,777 | |
| Ascendis Pharma | ORDINARY SHARES | K08588103 | 1,363 | 12.2% | 5,111,111 | New+5,111,111 | |
| Krystal Biotech IncKRYS | Common | 501147102 | 1,074 | 9.6% | 2,888,888 | Unchanged | |
| Madrigal Pharmaceuticals IncMDGL | Common | 558868105 | 984 | 8.8% | 1,833,333 | Added+15,152 | |
| Argenx SEARGX | Sponsored ADR | 04016X101 | 928 | 8.3% | 1,000,000 | Unchanged | |
| Arrowhead Pharmaceuticals IncARWR | Common | 04280A100 | 926 | 8.3% | 11,355,555 | Added+655,556 | |
| Kymera Therapeutics IncKYMR | Common | 501575104 | 857 | 7.7% | 7,474,747 | Unchanged | |
| Revolution Medicines IncRVMD | Common | 76155X100 | 430 | 3.9% | 2,297,000 | Reduced−47,444 | |
| Cytokinetics IncCYTK | Common | 23282W605 | 426 | 3.8% | 4,999,999 | Added+1,666,666 | |
| Celcuity IncCELC | Common | 15102K100 | 356 | 3.2% | 3,400,000 | Added+25,000 | |
| Structure Therapeutics IncGPCR | SPONSORED ADS | 86366E106 | 352 | 3.2% | 6,555,555 | Unchanged | |
| Xenon Pharmaceuticals IncXENE | Common | 98420N105 | 349 | 3.1% | 5,777,777 | Unchanged | |
| Definium Therapeutics IncDFTX | Common | 24477V105 | 338 | 3.0% | 7,188,888 | Added+2,188,888 | |
| Uniqure NV | Common | N90064101 | 310 | 2.8% | 6,727,777 | Added+768,182 | |
| Vera Therapeutics IncVERA | Common | 92337R101 | 246 | 2.2% | 5,723,888 | Reduced−165,000 | |
| Taysha Gene Therapies IncTSHA | Common | 877619106 | 163 | 1.5% | 23,888,888 | Added+2,188,888 | |
| Ocular Therapeutix IncOCUL | Common | 67576A100 | 123 | 1.1% | 12,540,000 | Added+225,000 | |
| Damora Therapeutics Inc | Common | 36322Q206 | 98.4 | 0.9% | 3,783,000 | Unchanged | |
| Hemab Therapeutics Holdings IncCOAG | Common | 423494103 | 70.7 | 0.6% | 1,925,150 | New+1,925,150 | |
| GH Research plc | ORDINARY SHARES | G3855L106 | 48.4 | 0.4% | 1,800,000 | Unchanged | |
| Viridian Therapeutics IncVRDN | Common | 92790C104 | 45.9 | 0.4% | 2,500,000 | Added+1,000,000 | |
| Septerna IncSEPN | Common | 81734D104 | 44.8 | 0.4% | 1,337,500 | Unchanged | |
| Avalo TherapeuticsAVTX | Common | 05338F306 | 43.1 | 0.4% | 2,333,333 | Added+923,333 | |
| Faeth Therapeutics IncFTH | COMMON | 81728A207 | 36.1 | 0.3% | 1,444,039 | New+1,444,039 | |
| Whitehawk Therapeutics IncWHWK | Common | 00032Q104 | 13.1 | 0.1% | 2,849,402 | Unchanged | |
| Lexeo Therapeutics IncLXEO | Common | 52886X107 | 6.9 | <0.1% | 1,489,189 | Reduced−385,811 |
Sold out: 9 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Alkermes plc | Common | G01767105 | 0.0 | 0.0% | 0 | Sold out−1,200,000 | |
| Apellis Pharmaceuticals Inc | Common | 03753U106 | 0.0 | 0.0% | 0 | Sold out−12,222,222 | |
| Ascendis Pharma | Sponsored ADR | 04351P101 | 0.0 | 0.0% | 0 | Sold out−5,062,500 | |
| Celcuity IncCELC | Common | 15102K100 | 0.0 | 0.0% | 0 | Call | Sold out−200,000 |
| Centessa Pharmaceuticals plc | SPONSORED ADS | 152309100 | 0.0 | 0.0% | 0 | Sold out−11,430,455 | |
| Mannkind CorpMNKD | Common | 56400P706 | 0.0 | 0.0% | 0 | Sold out−2,200,000 | |
| Soleno Therapeutics Inc | Common | 834203309 | 0.0 | 0.0% | 0 | Sold out−2,300,000 | |
| Terns Pharmaceuticals Inc | Common | 880881107 | 0.0 | 0.0% | 0 | Sold out−5,695,000 | |
| United Therapeutics CorpUTHR | Common | 91307C102 | 0.0 | 0.0% | 0 | Call | Sold out−380,000 |
Source: SEC EDGAR, Form 13F-HR, accession 0001104659-26-096427 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.